Peripheral nerve diseases

Antibiotics for the neurological complications of Lyme disease

Abstract Background Various central nervous system-penetrant antibiotics are bactericidal in vitro and in vivo against the causative agent of Lyme neuroborreliosis (LNB), Borrelia burgdorferi. These antibiotics are routinely used clinically to treat LNB, but their relative efficacy is not clear. Objectives To assess the effects of antibiotics for the treatment of LNB. Search methods On […]

Share

Treatment for ulnar neuropathy at the elbow

Abstract Background Ulnar neuropathy at the elbow (UNE) is the second most common entrapment neuropathy after carpal tunnel syndrome. Treatment may be conservative or surgical, but optimal management remains controversial. This is an update of a review first published in 2010 and previously updated in 2012. Objectives To determine the effectiveness and safety of conservative […]

Share

Corticosteroids for Guillain -Barré syndrome

Abstract Background Guillain‐Barré syndrome (GBS) is an acute paralysing disease caused by inflammation of the peripheral nerves, which corticosteroids would be expected to benefit. Objectives To examine the ability of corticosteroids to hasten recovery and reduce the long‐term morbidity from GBS. Search methods On 12 January 2016, we searched the Cochrane Neuromuscular Specialised Register, the […]

Share

Fentanyl for neuropathic pain in adults

Abstract Background Opioid drugs, including fentanyl, are commonly used to treat neuropathic pain, and are considered effective by some professionals. Most reviews have examined all opioids together. This review sought evidence specifically for fentanyl, at any dose, and by any route of administration. Other opioids are considered in separate reviews. Objectives To assess the analgesic […]

Share

Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies

Abstract Background Serum monoclonal anti‐myelin‐associated glycoprotein (anti‐MAG) antibodies may be pathogenic in some people with immunoglobulin M (IgM) paraprotein and demyelinating neuropathy. Immunotherapies aimed at reducing the level of these antibodies might be expected to be beneficial. This is an update of a review first published in 2003 and previously updated in 2006 and 2012. […]

Share

Corticosteroids for treating nerve damage in leprosy

Abstract Background Leprosy causes nerve damage that can result in nerve function impairment and disability. Corticosteroids are commonly used for treating nerve damage, although their long‐term effect is uncertain. This is an update of a review first published in 2007, and previously updated in 2009 and 2011. Objectives To assess the effects of corticosteroids on […]

Share

Rehabilitation following carpal tunnel release

Abstract Background Various rehabilitation treatments may be offered following carpal tunnel syndrome (CTS) surgery. The effectiveness of these interventions remains unclear. This is the first update of a review first published in 2013. Objectives To review the effectiveness and safety of rehabilitation interventions following CTS surgery compared with no treatment, placebo, or another intervention. Search […]

Share

Ascorbic acid for the treatment of Charcot-Marie-Tooth disease

Abstract Background Charcot-Marie-Tooth disease (CMT) comprises a large group of different forms of hereditary motor and sensory neuropathy. The molecular basis of several CMT subtypes has been clarified during the last 20 years. Since slowly progressive muscle weakness and sensory disturbances are the main features of these syndromes, treatments aim to improve motor impairment and […]

Share

Psychological therapies for the management of chronic neuropathic pain in adults

Abstract Background Neuropathic pain is thought to arise from damage to the somatosensory nervous system. Its prevalence is increasing in line with many chronic disorders such as diabetes. All treatments have limited effectiveness. Given the evidence regarding psychological treatment for distress and disability in people with various chronic pain conditions, we were interested to investigate […]

Share

Oral nonsteroidal anti-inflammatory drugs for neuropathic pain

Abstract Background Although often considered to be lacking adequate evidence, nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used in the management of neuropathic pain. Previous surveys found 18% to 47% of affected people reported using NSAIDs specifically for their neuropathic pain, although possibly not in the United Kingdom (UK). Objectives To assess the analgesic efficacy of […]

Share
  • The review abstracts published on this site are the property of John Wiley & Sons, Ltd., and of the Cochrane Review Groups that have produced the reviews.
Share
Share